Seed/Nut/Grain Variants · Seed Oils
Evening Primrose Oil (Oenothera biennis) (Oenothera biennis)
Preliminary EvidenceCompound
Hermetica Superfood Encyclopedia
Evening primrose oil is a seed oil rich in gamma-linolenic acid (GLA), an omega-6 fatty acid that the body converts to dihomo-gamma-linolenic acid (DGLA) and subsequently to anti-inflammatory prostaglandin E1 (PGE1). This prostaglandin cascade modulates inflammatory signaling, hormone sensitivity, and nerve conduction, underpinning its clinical applications in mastalgia, menopausal symptoms, and diabetic neuropathy.
Evening primrose oil is extracted from the seeds of Oenothera biennis, a biennial plant native to North America and widely cultivated in Europe. The oil is obtained through cold-pressing of the seeds, yielding a rich source of omega-6 essential fatty acids, particularly containing 8-9% gamma-linolenic acid (GLA).
A 2021 systematic review and meta-analysis of 13 RCTs (1,017 participants) found evening primrose oil superior to placebo for mastalgia pain reduction and comparable to topical NSAIDs. Additional RCTs demonstrated benefits for menopausal symptoms (PMID: 31738736), diabetic neuropathy (PMID: 40418820), and atopic eczema (PMID: 17168667), with a systematic review supporting use for inflammatory diseases (PMID: 38360611).
Clinically studied doses range from 1,000 mg daily to 1,000 mg every 12 hours (2,000 mg/day) in soft gel capsules, typically taken for 4-8 weeks for conditions like neuropathy and menopausal symptoms. For mastalgia and PMS, various oral doses have been used over 1-6 months. Consult a healthcare provider before starting any new supplement.
Evening Primrose Oil is a polyunsaturated fatty acid-rich seed oil with a distinctive gamma-linolenic acid (GLA) profile. **Primary fatty acid composition:** Linoleic acid (LA, 18:2 n-6): 65–80% of total fatty acids; Gamma-linolenic acid (GLA, 18:3 n-6): 7–14% (typically ~10%, or approximately 80–100 mg per 1,000 mg capsule); Oleic acid (18:1 n-9): 5–12%; Palmitic acid (16:0): 6–10%; Stearic acid (18:0): 1–3%; trace amounts of alpha-linolenic acid (ALA, <0.5%). **Caloric content:** ~9 kcal per gram (as with all dietary fats); a standard 1,000 mg softgel provides ~9 kcal. **Bioactive compounds:** GLA is the principal bioactive; it is a direct precursor to dihomo-gamma-linolenic acid (DGLA), which is metabolized to anti-inflammatory series-1 prostaglandins (PGE1) and 15-hydroxydihomo-gamma-linolenic acid (15-HETrE), both of which modulate inflammation. The oil also contains minor amounts of polyphenolic compounds including gallic acid and catechin derivatives, as well as phytosterols (primarily β-sitosterol at ~50–100 mg/100 g oil, with campesterol and stigmasterol in smaller quantities), which contribute modest cholesterol-lowering and anti-inflammatory activity. Tocopherols are present as natural antioxidants: predominantly gamma-tocopherol (~15–30 mg/100 g) with smaller amounts of alpha-tocopherol (~2–5 mg/100 g), providing some vitamin E activity and oxidative stability. **Micronutrients:** The refined oil is essentially devoid of significant vitamins (A, D, K, B-complex), minerals, fiber, and protein. **Bioavailability notes:** Oral GLA bioavailability is generally good when consumed with food containing dietary fat, which enhances micellar solubilization and absorption. Conversion of GLA → DGLA occurs readily via elongase enzymes, bypassing the rate-limiting delta-6-desaturase step required for LA → GLA conversion, which is often impaired in aging, diabetes, and inflammatory states — this bypass mechanism is considered the therapeutic rationale for direct GLA supplementation. Peak plasma GLA/DGLA levels are typically reached within 2–4 weeks of consistent daily supplementation (typically 1,000–3,000 mg EPO daily, providing ~80–300 mg GLA). Enteric-coated or emulsified formulations may reduce GI side effects but do not substantially alter overall bioavailability. The oil is susceptible to oxidative degradation; cold-pressed, nitrogen-flushed preparations in opaque softgels maintain superior bioactive integrity.
Evening primrose oil delivers gamma-linolenic acid (GLA, ~8–10% of total fatty acids), which bypasses the rate-limiting delta-6-desaturase enzyme step and is rapidly elongated to dihomo-gamma-linolenic acid (DGLA) by fatty acid elongase. DGLA competes with arachidonic acid (AA) at cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, shifting eicosanoid production away from pro-inflammatory prostaglandin E2 (PGE2) and leukotriene B4 toward anti-inflammatory prostaglandin E1 (PGE1). PGE1 also modulates prolactin receptor sensitivity in breast tissue and supports myelin sheath integrity in peripheral neurons by improving endoneurial blood flow through vasodilatory prostanoid signaling.
A meta-analysis of 13 RCTs enrolling 1,017 participants found evening primrose oil (GLA 240–720 mg/day) significantly reduced cyclical and non-cyclical mastalgia severity compared to placebo, with the effect being most robust for cyclical breast pain. A double-blind RCT (n=189, PMID: 31738736) demonstrated significant improvements in menopausal psychological symptoms including hot flush severity and mood disturbance after 8 weeks versus placebo. Evidence for painful diabetic neuropathy improvement comes from smaller RCTs showing enhanced nerve conduction velocity and reduced pain scores with 360–480 mg GLA daily over 6–12 months, though sample sizes limit generalizability. Overall, the evidence for mastalgia is strongest (high-quality meta-analytic data), while neuropathy and menopause data remain promising but require larger confirmatory trials.
Evening primrose oil is generally well-tolerated at doses of 2–6 g/day; most commonly reported adverse effects are mild gastrointestinal symptoms including nausea, soft stools, and bloating. It exhibits antiplatelet activity through PGE1-mediated inhibition of platelet aggregation, creating a clinically relevant interaction with anticoagulants (warfarin, heparin) and antiplatelet drugs (aspirin, clopidogrel) that may increase bleeding risk. Evening primrose oil should be used with caution in individuals with epilepsy or those taking phenothiazine antipsychotics (e.g., chlorpromazine), as GLA may lower the seizure threshold. Safety during pregnancy has not been established in controlled trials; historical use for cervical ripening lacks sufficient evidence, and routine supplementation during pregnancy is not recommended without medical supervision.
